LYELL IMMUNOPHARMA ($LYEL) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.18 per share, beating estimates of -$0.18 by $0.00. The company also reported revenue of $10,000, beating estimates of $0 by $10,000.
You can see Quiver Quantitative's $LYEL stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LYELL IMMUNOPHARMA Insider Trading Activity
LYELL IMMUNOPHARMA insiders have traded $LYEL stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LYEL stock by insiders over the last 6 months:
- SUMANT RAMACHANDRA purchased 200,000 shares for an estimated $115,219
- CHARLES W. NEWTON (Chief Financial Officer) purchased 200,000 shares for an estimated $111,620
- LYNN SEELY (President and CEO) purchased 175,000 shares for an estimated $106,190
- RICHARD KLAUSNER purchased 158,000 shares for an estimated $94,942
- OTIS W BRAWLEY purchased 35,640 shares for an estimated $19,958
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
LYELL IMMUNOPHARMA Hedge Fund Activity
We have seen 46 institutional investors add shares of LYELL IMMUNOPHARMA stock to their portfolio, and 67 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FORESITE CAPITAL MANAGEMENT V, LLC added 8,133,047 shares (+inf%) to their portfolio in Q4 2024, for an estimated $5,205,150
- VENBIO PARTNERS LLC added 7,102,190 shares (+inf%) to their portfolio in Q4 2024, for an estimated $4,545,401
- CITADEL ADVISORS LLC added 3,752,968 shares (+211196.8%) to their portfolio in Q4 2024, for an estimated $2,401,899
- ORBIMED ADVISORS LLC removed 2,982,378 shares (-49.0%) from their portfolio in Q4 2024, for an estimated $1,908,721
- RENAISSANCE TECHNOLOGIES LLC added 1,414,746 shares (+716.7%) to their portfolio in Q4 2024, for an estimated $905,437
- OPALEYE MANAGEMENT INC. removed 1,395,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $892,800
- JACOBS LEVY EQUITY MANAGEMENT, INC added 1,385,301 shares (+inf%) to their portfolio in Q4 2024, for an estimated $886,592
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
